Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion

ABSTRACT Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study. The primary outcome was the incidence rate of ASN at month 6. The secondary outcomes were the mean changes from baseline in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography over time to month 12. Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham group and 3 (37.50%) eyes in the IVTA group, during 12 months of fol low-up (p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG required surgery and developed in one eye despite laser treatment. Conclusion: Early treatment with intravitreal antivascular endothelial growth factor therapy decreases the rates of ASN and NVG after CRVO.

Saved in:
Bibliographic Details
Main Authors: Lucatto,Luiz Filipe Adami, Magalhães-Junior,Octaviano, Prazeres,Juliana M. B., Ferreira,Adriano M., Oliveira,Ramon A., Moraes,Nilva S., Hirai,Flávio E., Maia,Mauricio
Format: Digital revista
Language:English
Published: Conselho Brasileiro de Oftalmologia 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492017000200097
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-27492017000200097
record_format ojs
spelling oai:scielo:S0004-274920170002000972017-06-01Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusionLucatto,Luiz Filipe AdamiMagalhães-Junior,OctavianoPrazeres,Juliana M. B.Ferreira,Adriano M.Oliveira,Ramon A.Moraes,Nilva S.Hirai,Flávio E.Maia,Mauricio Neovascularization Pathologic Bevacizumab Retinal vein occlusion Macular edema Glaucoma Neovascular ABSTRACT Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study. The primary outcome was the incidence rate of ASN at month 6. The secondary outcomes were the mean changes from baseline in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography over time to month 12. Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham group and 3 (37.50%) eyes in the IVTA group, during 12 months of fol low-up (p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG required surgery and developed in one eye despite laser treatment. Conclusion: Early treatment with intravitreal antivascular endothelial growth factor therapy decreases the rates of ASN and NVG after CRVO.info:eu-repo/semantics/openAccessConselho Brasileiro de OftalmologiaArquivos Brasileiros de Oftalmologia v.80 n.2 20172017-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492017000200097en10.5935/0004-2749.20170024
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Lucatto,Luiz Filipe Adami
Magalhães-Junior,Octaviano
Prazeres,Juliana M. B.
Ferreira,Adriano M.
Oliveira,Ramon A.
Moraes,Nilva S.
Hirai,Flávio E.
Maia,Mauricio
spellingShingle Lucatto,Luiz Filipe Adami
Magalhães-Junior,Octaviano
Prazeres,Juliana M. B.
Ferreira,Adriano M.
Oliveira,Ramon A.
Moraes,Nilva S.
Hirai,Flávio E.
Maia,Mauricio
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion
author_facet Lucatto,Luiz Filipe Adami
Magalhães-Junior,Octaviano
Prazeres,Juliana M. B.
Ferreira,Adriano M.
Oliveira,Ramon A.
Moraes,Nilva S.
Hirai,Flávio E.
Maia,Mauricio
author_sort Lucatto,Luiz Filipe Adami
title Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion
title_short Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion
title_full Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion
title_fullStr Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion
title_full_unstemmed Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion
title_sort incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion
description ABSTRACT Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study. The primary outcome was the incidence rate of ASN at month 6. The secondary outcomes were the mean changes from baseline in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography over time to month 12. Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham group and 3 (37.50%) eyes in the IVTA group, during 12 months of fol low-up (p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG required surgery and developed in one eye despite laser treatment. Conclusion: Early treatment with intravitreal antivascular endothelial growth factor therapy decreases the rates of ASN and NVG after CRVO.
publisher Conselho Brasileiro de Oftalmologia
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492017000200097
work_keys_str_mv AT lucattoluizfilipeadami incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion
AT magalhaesjunioroctaviano incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion
AT prazeresjulianamb incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion
AT ferreiraadrianom incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion
AT oliveiraramona incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion
AT moraesnilvas incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion
AT hiraiflavioe incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion
AT maiamauricio incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion
_version_ 1756373233872928768